Venglustat for Gaucher disease type 3
The FDA is expected to decide on Venglustat for Gaucher disease type 3 by November 25, 2026, under a NDA from Sanofi.
What is being decided
Sanofi has a NDA under FDA review for Venglustat in Gaucher disease type 3. Oral brain-penetrant therapy for the neurological form of Gaucher disease.
Who this decision matters to
Gaucher disease is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase, resulting in accumulation of fatty substances in the spleen, liver, and bone marrow. This buildup causes bone pain, splenomegaly, anemia, thrombocytopenia, and progressive organ damage. Multiple treatment options including enzyme replacement and substrate reduction therapies are available.
Prevalence: 1 in 40,000 to 60,000 in general population; 1 in 850 among Ashkenazi Jewish population. See our full Gaucher Disease page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Gaucher Disease treatment stands today
Gene therapy and improved disease-modifying therapies are opening new horizons for Gaucher disease management. Clinical trials continue evaluating gene therapy approaches, next-generation enzyme replacement formulations, and novel substrate reduction inhibitors that may offer improved efficacy, dosing convenience, or better tolerability. The International Collaborative Gaucher Group and Gaucher Disease Support Group maintain trial registries. Genetic counseling helps families understand inheritance patterns and plan for future pregnancies. If diagnosed with Gaucher disease, work with your metabolic specialist to understand all available treatment options, as newer agents continue to emerge with potentially superior benefits over earlier therapies.
Meanwhile, 29 Gaucher Disease trials are recruiting
Whatever the FDA decides here, research on Gaucher Disease does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Gaucher Disease
Get notified when new gaucher-disease trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Venglustat?
The FDA's target decision date (PDUFA date) for Venglustat in Gaucher disease type 3 is November 25, 2026, disclosed by Sanofi. The agency can act before this date and occasionally runs past it.
What is Venglustat being reviewed for?
Sanofi submitted a NDA for Venglustat in Gaucher disease type 3. Oral brain-penetrant therapy for the neurological form of Gaucher disease.
What happens after the Venglustat decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Sanofi press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.